hexokinase

2-Deoxy-D-glucose (2-DG) is an analog of glucose, an inhibitor of glycolysis. 2-Deoxy-D-glucose has antiviral activity, as well as inhibitory cell proliferation and apoptosis-inducing activity.

Lonidamine (Diclondazolic Acid) is an indazole carboxylic acid derivative, principally inhibiting aerobic glycolytic activity, by its effect on mitochondrially-bound hexokinase (HK).

3-Bromopyruvic acid (Hexokinase II Inhibitor II, 3-BP) is a hexokinase II inhibitor with Ki of 2.4 mM for glycolysis/hexokinase inhibition. It is inhibitor of tumour cell energy metabolism and chemopotentiator of platinum drugs.

Benitrobenrazide (Hexokinase 2 inhibitor 1) is a hexokinase 2 inhibitor with anticancer and antitumor activity.Benitrobenrazide inhibits the growth of tumors and can be used in cancer research.

HexokinaseIIVDACbinding domain peptide (Hxk2VBD peptide) is a cell-permeable peptide derived from the hexokinase II VDAC binding domain. This peptide inhibits the mitochondrial localization of hexokinase 2 (HXK2) and also suppresses neurotrophic factor-induced axon growth.

PF-04937319 is an activator of glucokinase (EC50 =154.4  μM). PF-04937319 maintains glucose-lowering efficacy while mitigating the risk of hypoglycemia observed with many other glucokinase activators. PF-04937319 can be used in research on the treatment of type 2 diabetes mellitus.

Globalagliatin (LY2608204) has been used in trials studying the treatment of Diabetes Mellitus, Type 2.

AMG-3969 is an effective glucokinase-glucokinase regulatory protein interaction (GK-GKRP) disruptor (IC50: 4 nM).

MK-0941 free base is an orally active glucokinase activator with potent glucose-lowering activity, making it a potential therapeutic agent for type 2 diabetes.

Dorzagliatin (HMS5552) is a dual-acting glucokinase (GK) activator. It also improves glycaemic control and pancreatic β-cell function in type 2 diabetes.

Palmitelaidic Acid (trans-Palmitoleic acid) is one of the most abundant fatty acids in serum and tissue.

AZD-1656 is a glucokinase activator (GKA) that can cause dose-limiting hypoglycemia in normal animals used in embryofetal development studies and type 2 diabetes.

AM-2394 is an effective and specific Glucokinase agonist (GKA, EC50: 60 nM), which catalyzes the phosphorylation of glucose to glucose-6-phosphate. AM-2394(AM2394) increases the affinity of GK for glucose by approximately 10-fold, exhibits moderate clearance and good oral bioavailability in multiple animal models, and lowers glucose excursion following an oral glucose tolerance test in an ob/ob mouse model of diabetes.

Hexokinase (ScHEX1), a glycolytic enzyme, is inhibited by n-acetylglucosamine, which causes it to detach from the mitochondrial outer membrane. This detachment activates the NLRP3 inflammasome [1].

D-mannoheptose is the main non-structural carbohydrate in avocado. D-mannoheptose is a specific inhibitor of D-glucose phosphorylation. D-mannoheptose can prevent the release of insulin and the utilization of carbohydrates in rats.

DNJNAc, also known as 2-Acetamido-1,2-dideoxynojirimycin, is a highly potent and specific inhibitor of β-hexosaminidase (HEX). HEX enzymes catalyze the hydrolysis of terminal non-reducing N-acetyl-β-D-glucosamine (GlcNAc) and N-acetyl-β-D-galactosamine (GalNAc) residues from glycoconjugates such as glycoproteins, gangliosides, and glycosaminoglycans. HEX secreted by chondrocytes into the extracellular space contributes to cartilage matrix degradation, and HEX activity is elevated in the synovial fluid of osteoarthritis patients.

SID 24785302 is an inhibitor of hexokinase, which can suppress glycolysis, regulate mitochondrial function, and ultimately inhibit the replication of mutant mitochondrial DNA.

HK-2-IN-1 is an inhibitor of Hexokinase 2 (HK-2). It exhibits non-activation effects on human recombinant HK-2 enzyme. HK-2-IN-1 possesses antitumor activity, impacting immune cells within the tumor microenvironment. It has immunomodulatory properties and is applicable in research on cancers such as colon cancer, liver cancer, and breast cancer.

2-deoxy-D-Glucose-13C is intended for use as an internal standard for the quantification of 2-deoxy-D-glucose by GC- or LC-MS. 2-deoxy-D-Glucose (T6742) is a glucose antimetabolite and an inhibitor of glycolysis. It inhibits hexokinase, the enzyme that converts glucose to glucose-6-phosphate, as well as phosphoglucose isomerase, the enzyme that converts glucose-6-phosphate to fructose-6-phosphate.

2-Deoxy-D-glucose-D is the deuterated form of 2-Deoxy-D-glucose (T6742). This compound is a glucose analogue that acts as a glucose metabolism inhibitor by targeting hexokinase to hinder glycolysis.

2-Deoxy-D-glucose-13C6 is a 13C-labeled variant of 2-Deoxy-D-glucose. As a glucose analog, 2-Deoxy-D-glucose (T6742) functions as a glucose metabolism inhibitor by targeting hexokinase, thereby disrupting glycolysis.

Metrizamide is a nonionic radiopaque contrast agent.

ADP-specific glucokinase, expressed in thermophilic archaea, is an ADP-specific enzyme that catalyzes the conversion of glucose to glucose-6-phosphate, thereby facilitating glycolysis. This enzyme can activate T cells and enhance the phagocytic activity of macrophages. It is used in research related to metabolic disorders, neurological diseases, and tumors.

Ketohexokinase inhibitor 1 is a ketohexokinase inhibitor (IC50s: 8.4 nM and 66 nM for KHK-C and KHK-A, respectively).